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Oncolytic virotherapy exploits live viruses with selective tropism for cancerous cells and tissues to treat
cancer. As discussed here, the field has progressed considerably as a result of both the successes and fail-
ures of previous and on-going clinical trials for various cancers. These studies indicate that oncolytic viruses
are remarkably safe and more efficacious when virus replication stimulates sustained antitumor immune
responses. In the future, virotherapy should be combined with immunomodulatory reagents that target
immune tolerance to established cancers.Introduction
The field of oncolytic virotherapy began as an observational sci-
ence more than a century ago when it was noted that cancer
regressions sometimes occurred spontaneously in patients
following certain viral infections, (Kelly and Russell, 2007). These
early anecdotes spawned a small number of clinical studies
beginning in the 1940s using unmodified, and sometimes
dangerous, test viruses. Although there were often glimmers of
activity in these studies, the field of anticancer viral therapy
languished for several decades, in part because of the early suc-
cess of chemo and radiation therapies but also due to our limited
understanding of the biology of these complex biological agents.
The recombinant DNA revolution of the last 30 years has now
provided the tools necessary to better understand, at the molec-
ular level, how viruses attack and usurp host cell machinery.
These advances coupled with those in the field of cancer biology
have reignited interest in the use of replicating viruses as cancer
therapeutics. Over the last two decades in particular, a variety of
DNA and RNA viruses shown or engineered to be selective for
cancer cells have transitioned from preclinical studies into early
phase clinical testing and more recently into randomized clinical
trials. The current status of ongoing clinical trials, and the candi-
date oncolytic viruses that are in various stages of development,
have been summarized in great detail within many recent re-
views, and the reader is encouraged to consult these for details
regarding specific viruses and cancers under active clinical
investigation today (for example, see Bourke et al., 2011; Don-
nelly et al., 2012, 2013; Eager and Nemunaitis, 2011; Russell
et al., 2012; Patel and Kratzke, 2013; Sze et al., 2013; Vacchelli
et al., 2013; Miest and Cattaneo, 2014). Our intent is to summa-
rize some of the general trends currently emerging based on the
clinical experiences to date, and to comment on the future
prospects for oncolytic virotherapy assuming a more prominent
role as a licensed modality that would join the current standard
therapeutic trio of clinical oncology practice: i.e. surgery,
chemotherapy and radiotherapy.
Oncolytic Viruses Target Cells with Malignantly Altered
Signaling Pathways
The startling recent advances in the sequencing of cancer
patient genomes continue to re-enforce the notion that cancer
is a complex, heterogeneous disease that defies treatment
with agents that target only a single genetic mutation. As260 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.Bert Vogelstein noted in 2008, to make significant advances
in cancer therapy, ‘‘the focus should shift from hunting for indi-
vidual genes that cause certain cancers, to disrupting broader
biological pathways that support cancer growth’’ (Hayden,
2008). We argue that oncolytic viruses are indeed just such
agents, because they thrive in tumor cells where pathways
are malignantly activated or disrupted and can exploit the de-
regulated metabolic processes that characterize cancerous
transformation. However, because different oncolytic viruses
likely benefit or even require specific alterations in host cell
pathways, it has been difficult to identify individual molecular
markers that predict specific antitumor efficacies for each on-
colytic virus. While this remains an active area of research,
the explanations for the precise tumor specificities of specific
viruses vary widely from one virus/cell scenario to the next
(Russell et al., 2012). Despite this, several overarching themes
have become apparent to rationalize selective virus targeting of
cancer cells. There is little doubt that the unbridled metabolism
of tumor cells provides a selective niche for many viruses that
benefit from dysregulated cell growth in general. Additionally,
most, if not all, cancer cells during the transformation process
undergo alterations that sacrifice elements of their potent
cellular, innate antiviral response pathways. Thus, cancer cells
in general become collectively susceptible to many more
viruses than their parental nontransformed cellular counterparts
and are often less responsive to the induction of the antiviral
state by self-protective cytokines such as the type I and II
interferons (IFNs) or tumor necrosis factor (TNF). There is a
complex array of cellular defenses that have developed over
evolution to combat virus infections, and, not surprisingly,
each successful virus family has developed different strategies
to overcome these collective antiviral responses, at least in
their specific evolutionary hosts. Given the diversity of genetic
alterations documented in cancer cells, it remains unlikely that
a single ‘‘magic bullet’’ virus will ever be identified that would
treat all cancers equally. Instead, viruses with differing cellular
attack mechanisms will have to be matched with pathway-spe-
cific cancer cell defects.
Delivery Issues: In vivo, In situ, Ex vivo, or FedEx?
Oncolytic viruses are quite unique as cancer therapeutics, since
they are capable of productive replication within the tumor
bed and have the potential to ‘‘self-amplify,’’ thus spreading
Table 1. Clinical Trials of Oncolytic Viruses
Virus Family Examples Genetic Modifications Target Cancers Clinical Trial Sponsor
Adenovirus Oncorine (H101) Ad-E1b Liver, lung, head/neck,
pancreas
Shanghai Sunway
(approved in China)
CGTG-102 Ad-GMCSF+ Solid tumors Oncos
DNX-2401 Ad-d24RGD Brain DNAtrix/Erasmus
Medical Center
ICOVIR-5 Ad-DM-E2F-K-d24RGD Melanoma Institut Catala d’Oncologia
CG0070 Ad-GMCSF+ Bladder Cold Genesys
Colo Ad1 Ad3:Ad11p hybrid Metastatic solid tumors PsiOxus
Herpesvirus T-VEC HSV1-ICP34.5/4GMCSF+ Melanoma Amgen/BioVex
(completed Phase III)
Seprehvir HSV1716-ICP34.5 Lung, various solid tumors Virttu Biologics and
Children’s Hospital
G207 HSV1-ICP34.5/6 Brain MediGene
HF10 HSV-HF strain Head/neck, skin, breast,
melanoma
Takara Bio
Poxvirus Pexa-Vec/JX594 Vaccinia Wyeth TK/
GMCSF+
Liver, colorectal,
head/neck, others
Jennerex (multiple trials)
GL-ONC1 Vaccinia Lister-GFP+
F14.5L/TK/A56R
Peritoneal cavity,
head/neck, others
GeneLux (multiple trials)
Paramyxovirus Measles virus MV-NIS+, MV-CEA+ Ovarian, peritoneal,
myeloma, others
Mayo Clinic/NCI (multiple trials)
Newcastle disease virus Natural isolate (HUJ) Glioblastoma multiforme,
neuroblastoma, sarcomas
Hadassah Medical Organization
Reovirus Reolysin Reovirus-serotype 3 Diverse cancers Oncolytics Biotech Inc
(multiple trials)
Rhabdovirus Vesicular somatitis virus VSV-IFNb+ Hepatocellular carcinoma Mayo Clinic
Maraba virus MAGE A3+/Matrix
glycoprotein mutations
Lung, colon, melanoma NCIC Clinical Trials Group
Picornavirus CAVATAK Coxsackievirus-A21 Melanoma Viralytics (multiple trials)
PVS-RIPO Polio:Rhino virus chimera Glioblastoma Duke University
Seneca Valley V. Natural isolate (NTX-010) Neuroendocrine tumors Children’s Oncology Group
Parvovirus H-1 PV Natural isolate Glioblastoma Heidelberg University Hospital
Cell Host & Microbe
Minireviewwithin and between tumors. This property allows them to be
administered in multiple different ways to the patient, including
systemic infusion, intratumoral injections, and/or combinations
thereof. For localized cancers, for instance, those contained
within the skull, it may be appropriate to use strategies like con-
vection-enhanced delivery, which uses a surgically implanted
catheter to focus the virus payload in the local vicinity of the brain
tumors. Similarly, in diseases like hepatocellular carcinoma,
where the standard of care includes locoregional therapy
through direct injections or radio frequency ablation, intratu-
moral virus administration is easily implemented. For patients
with metastatic disease, it seems reasonable to propose that
intravascular infusion would be the preferred route, as it poten-
tially provides access to all vascularized tumor sites within the
body. However, if virus-induced acquired antitumor immunity
is in fact the end goal, the blanket infection of every available
cancer cell in situ may not be necessary. For example, the recent
Amgenmelanoma trial (see Table 1) is a clear example where the
effective treatment of metastatic disease was accomplished
through direct peripheral tumor injections. In this case, the in-duction of systemic antitumor immunity in therapy responders
was accomplished by the direct infection of only a limited subset
of tumor lesions manifested by the patient.
In contrast to treating cancer in situ, one particular subset of
virotherapy is to target and eliminate potential cancer cells that
can contaminate self-transplant tissues or cells ex vivo, prior to
tissue engraftment into the patient. This ex vivo purging strategy
offers the prospects of delivering oncolytic virus to all of the po-
tential cancer cells within a given patient transplant sample (for
example, in order to eliminate even low levels of cancer stem
cells that might reside within an autologous hematopoietic
stem cell transplant specimen) (Rahman et al., 2010).
Another virus delivery strategy that has received a great deal
of attention but has not yet been exploited in oncolytic virother-
apy clinical trials involves using patient cells as virus carriers.
This delivery mechanism uses cells, particularly immune cells
that exhibit a natural predilection to migrate to tumor sites
within the body, as cellular carriers that can be infected with
therapeutic virus ex vivo, then infused back into the patient
with the hope that they will deliver live oncolytic virus to distantCell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 261
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This has been called the ‘‘Trojan Horse’’ strategy (or, less
historically, FedEx delivery of virus to the cancer tissue zip
code) and has proven effective in a variety of animal models.
One of the issues remaining prior to clinical development of
this strategy has been how to best identify the most effective
carrier cell for any individual cancer patient. Many cell can-
didates are under testing as potential carriers for oncolytic
viruses in preclinical models (for example, tumor-infiltrating
lymphocytes or mesenchymal stem cells) (Willmon et al.,
2009). On the clinical front, a virus:cell carrier platform was
recently developed that couples autologous adipose-derived
mesenchymal stem cells with an oncolytic measles virus
(Mader et al., 2013), and this antitumor strategy received US
FDA approval to move into clinical testing in ovarian cancer
patients early in 2014.
Is Oncolytic Virotherapy Really Anticancer
Immunotherapy in Disguise?
The definition of what precisely constitutes ‘‘oncolytic virother-
apy’’ has become increasingly more blurred as it becomes clear
that any oncolytic virus can be viewed in different perspectives.
For example, oncolytic viruses can be considered as delivery
vehicles for death signals specific for cancer cells, as gene ther-
apy vectors for expression of therapeutic anticancer genes, or
as oncotropic agents with immunostimulatory properties that
upregulate antitumor immunity. Perhaps the single biggest
change in our thinking about how to develop oncolytic virother-
apy is the recognition that it is no longer regarded as critical for
the therapeutic virus to directly infect and kill every last cancer
cell in the patient. Instead, the most successful virotherapy re-
sults in the virus-induced triggering of more effective antitumor
immune responses and/or the diminishment of immune sup-
pression that shields tumor cells (sometimes called breaking
immune tolerance). Induced antitumor immune responses that
can follow active virus replication within tumor beds have
emerged as key determinants of successful anticancer virother-
apy (Tong et al., 2012; Bartlett et al., 2013). Indeed, some
patients undergoing oncolytic virotherapy seem to spontane-
ously undergo a dramatic and therapeutic transition from
induced antiviral responses against the oncolytic vector and
then progress onto more effective acquired antitumor immunity.
Those patients who have developed enhanced antitumor im-
mune responses following oncolytic virotherapy can be called
‘‘elite responders’’ and have the highest chances to go on to du-
rable disease regressions. Currently, the biggest challenge to
the oncolytic virotherapy field is to now carefully study virus-
treated patients who become elite responders well after the
input virus has been eliminated from their systems. It will be
critical to follow the detailed phenotypic characteristics of this
patient subset, both before and after their virotherapy regimen,
to assess if there are any trackable immune or genetic parame-
ters that can be correlated with their elite responder status.
Criteria that assess immune responses, such as HLA-profiles,
cytokine expression levels, immune cell activation stages,
changes in antitumor antibodies, suppressor cell activation
levels, etc., all need to be evaluated to identify measureable
parameters that can be used to preidentify elite responders a
priori and characterize those patient markers that specifically
correlate with tumor regressions.262 Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc.It is reasonable to posit that elite responders somehow
engage their cellular immune systems to respond more effec-
tively to tumor cell epitopes after virotherapy treatment.
Assuming that selective virus replication within at least some
of the tumor beds within a patient is a prerequisite for this
response, there are several possible mechanistic explanations.
For example, the cellular cytopathologies caused by productive
virus replication in target cancerous tissues could result in
improved, or altered, antigen presentation pathways that prime
reactive lymphocytes against tumor epitopes. Alternatively,
the support for cancer cells provided by resident stromal cells
or inflammatory myeloid cells might become compromised.
These important support cells can include regulatory immune
cells that protect the cancer microenvironment from effective
antitumor immunity, inflammatory cells and fibroblastic cells
that produce supportive cytokines and growth factors, as well
as newly acquired vascular beds that feed the tumors. Thus,
disruption of these support cells might allow more leeway for
effective acquired immune response pathways to develop
against cancer cells. Finally, virotherapy in the elite responder
patients might be a trigger to break immune tolerance, either
by compromising the functioning of resident immune suppres-
sor cells that infiltrate the tumors (such as regulatory T lympho-
cytes) or by causing a more global tissue support imbalance
that destabilizes local tumor-educated but anergic T cells or
myeloid suppressor cells. Perhaps the most intriguing possi-
bility to tip the balance further in this therapeutic direction
lies in the prospects that certain chemotherapeutic drugs, or
immunomodulatory reagents, have been used to achieve an
elite responder status in more patients (Ottolino-Perry et al.,
2010; Melcher et al., 2011; Tong et al., 2012; Wennier et al.,
2012). With more complete information about the immune
pathways that are specifically triggered by viral infection in
tumor tissues of elite responders, it should be possible
to devise specific therapeutic strategies to more effectively
skew patient immune responses to more effective anticancer
modalities.
More detailed studies of elite responders are critical to the
field, because current animal models do not reflect the accurate
range of immunological backgrounds encountered in true human
cancers. The two major classes of animal cancer models used
to evaluate candidate oncolytic viruses prior to clinical trial are
xenograft models of human cancer in immunodeficient mice
and variously derived syngeneic/genetic cancers within immu-
nocompetent animal hosts. The advantage of the former class
of models is that the replication properties of the test virus can
be studied within bona fide human cancer cells, but the
drawback is that the cancer graft can only be maintained under
immunodeficiency conditions in the recipient test host. Also, the
coterie of support stromal and inflammatory cells that are
commonly found in true human tumors are frequently absent in
the xenograft models. The advantage of the second class of
models is that the host animal immune system can be intact,
and even accurately mimic some of the immune tolerance as-
pects found in human cancers, but the cancer cells themselves
are not human and may exhibit very different tropism properties
with respect to the test viruses. Furthermore, the support
interactions with stromal or inflammatory cells within tumor
beds can be quite different from those found in the human
Cell Host & Microbe
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have been well-crafted for safety, the efficacy profiles have
been essentially unpredicted by the animal models used to
validate the choices of cancer targets and delivery modalities
used for the trial.
DevisingCombination Strategies to Improve Virotherapy
Efficacy
One of the more exciting developments in current investigative
oncology lies in the development of drugs and therapeutics
that target the endogenous suppressor leukocytes thought to
dampen effective immune responses to cancer (Vanneman
and Dranoff, 2012; Gao et al., 2013; Ribas and Wolchok,
2013). Reagents such as monoclonal antibodies targeting the
immune inhibitory molecules PD1, PD1L, or CTLA4 are under
development as immune adjuvants to selectively assist in
breaking tolerance to tumor antigens within cancer patients,
often with the prospects of boosting the efficacy of cancer vac-
cines, but such reagents should also be particularly effective as
combinatorial therapeutics with oncolytic viruses (Ottolino-Perry
et al., 2010; Melcher et al., 2011; Tong et al., 2012). Although one
potential concern is that inhibition of immune suppressor path-
ways might exacerbate viral infections (Frebel and Oxenius,
2013), the oncolytic viruses tested to date have proven to be
remarkably safe even in the most severely immunosuppressed
patients or immunodeficient animals. However, the potential
for runaway virus infections in a specific subset of patients
receiving multiple modalities of immunotherapy in addition to
virotherapy cannot be eliminated entirely, and clinical vigilance
will need to be continually exercised.
In some respects, immunological augmentation of oncolytic
virotherapy is already being tested, in that several oncolytic
viruses in clinical trial have been engineered to express proim-
mune cytokines, such as GM-CSF or IFN-b (see Table 1) (Else-
dawy and Russell, 2013). Also, a number of chemotherapeutic
drugs in use, such as the nucleoside analog gemcitabine, are
already known to reduce the activity of endogenous immune
suppressor cells and are potentially synergistic with a variety
of oncolytic viruses (Ottolino-Perry et al., 2010; Tong et al.,
2012; Wennier et al., 2012). It remains to be seen whether
the most attractive clinical course will be to attempt to
compromise immune tolerance from the beginning of the viro-
therapy or whether it improves efficacy to first promote tran-
sient immunosuppression to allow for a longer time window
for virus replication and dissemination, followed by suppressor
immunomodulation with targeted drug therapies. Although an-
imal models can provide clues as to the best strategy, there is
simply no substitute for rational approaches to clinical trials.
Lessons Learned (and Learning!) from Oncolytic
Virotherapy Clinical Trials
In the laboratory with particular mouse models, oncolytic viruses
can be exceedingly effective, with a single dose leading to com-
plete and long-lasting cures (Naik et al., 2012). However, even in
well-controlled settings with clonal tumor cell lines, there are
numerous mouse models that are refractory to monotherapy.
These ‘‘preclinical failures’’ have been incredibly informative
and as described above have advanced concepts in the field,
including a better understanding of the importance of the tumor
microenvironment, innate/adaptive immune responses, and the
challenges associated with tumor heterogeneity. Not surpris-ingly, the path to clinical approval of oncolytic viral therapeutics
has not been a straight line, and, as of 2013, no oncolytic viruses
have yet been approved by regulatory agencies in the US or EU.
There are over a dozen candidate viruses undergoing in excess
of 30 approved clinical trials around the world, and the likelihood
continues to grow that at least some of these viruses will receive
approval in the US/EU markets at some point in the future. Table
1 illustrates a representative spectrum of oncolytic virus trials
currently in progress in 2013, as registered by the National
Cancer Institute at clinicaltrials.gov, or that are about to be
launched.
Results from clinical studies are now supporting several key
concepts first uncovered in mouse tumor models: (1) oncolytic
viruses can be delivered systemically to sites of metastatic
disease by intravenous infusion, (2) physical barriers that limit
intravenous virus delivery can be overcome by dose escalation,
(3) tumor cells are not the only therapeutic targets of many onco-
lytic viruses (for example, the tumor vasculature), and (4) immune
cells can be both dose-limiting barriers and protherapeutic
carriers of oncolytic viruses (Breitbach et al., 2011,2013; Adair
et al., 2012).
As with our mouse experiments, it is important to recognize
and learn from the ‘‘clinical failures.’’ For example, the low
response rate in early trials that used the reovirus-based agent
Reolysin as a monotherapy led to this virus being tested in com-
bination with chemotherapy in ongoing randomized trials. The
Jennerex Biotherapeutics virus, Pexa-Vec (JX-594), which con-
sists of an attenuated vaccinia virus carrying the gene encoding
GM-CSF, recently failed to show a survival benefit over best
supportive care in a randomized Phase 2 study in second line
hepatocellular carcinoma (HCC) patients. As we now better
recognize the critical importance of virus-initiated antitumor
immune responses for long-term survival, it becomes even
more critical to design virotherapy trials to include patients
whose projected median survival will provide ample time to
mount an effective therapeutic immune response to their can-
cers. Indeed, in a small Phase 2 trial in front line patients with
HCC, a survival benefit was observed following Pexa Vec ther-
apy (Heo et al., 2013), suggesting that, as a monotherapy, this
virus should best be tested in patients earlier in their disease
progression, when they possess more robust immune response
capabilities.
Perhaps the single most remarkable observation made to date
is that, after more than two decades of trials and literally thou-
sands of patients, there have been no oncolytic-virotherapy-
attributed deaths, and the frequency of clinically serious adverse
events has remained remarkably low, especially when compared
to the standard regimens of chemotherapy, surgery, and radia-
tion. This is an even more impressive statistic if one takes into
account that most of the cancer patients enrolled in virotherapy
trials have already failed standard-of-care therapies and have
entered the trial only after their cancers have been sculpted
into increasingly treatment-refractory diseases by virtue of their
previous intervention failures. Indeed, for those trials where
both treated/failed and previously untreated patients have
been enrolled (such as the recent Amgen trials for metastatic
melanoma), it will be highly instructive to compare detailed
response level and survival benefit between these two patient
populations.Cell Host & Microbe 15, March 12, 2014 ª2014 Elsevier Inc. 263
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Despite the impressive progress to date, key challenges remain
before oncolytic viruses will become the fourth pillar of ap-
proved clinical oncology. It is now clear that oncolytic viruses
cannot be viewed as stand-alone therapies for any cancer.
Instead, they should be regarded as potentially powerful
adjuncts to the standard-of-care armamentarium and will
likely function best in combination with immunotherapies that
improve acquired immune responses against cancers that
have already been selected within the individual patient for
functional tolerance. The prospect is remote that any single on-
colytic virus treatment will infect and kill every last cancer cell
within any given patient, including potential cancer stem cells
that may remain quiescent and refractory within tissue niches
that are inaccessible to virus. It is also clear that cancer tissues
are heterogeneous and always include complex mixtures of
transformed cancer cells that are variably permissive to the on-
colytic virus and which are supported by a complex colony of
nontransformed support cells that may or may not be suscepti-
ble to the virus. Also, malignant cells can evolve resistance to
specific viruses over time, much like they can for chemothera-
peutic drugs, monoclonal antibodies, or antitumor cytokines
such as TNF or TRAIL, and so there is a limited window of op-
portunity for any one unique virotherapeutic to be effective. Se-
rial dosing with antigenically distinct oncolytic viruses might
offer one alternative strategy to outpace acquired immune
compromise of therapeutic virotherapy. Delivery issues remain
as well, but the most critical challenge is to identify which virus
and delivery method best optimizes the engagement of patient
immune cells that mediate the transition to acquired effector
immunity against tumor antigens. This transition appears to
occur spontaneously in elite responder patients but likely can
be specifically triggered with the appropriate cotherapies in
other cancer patients as well. But, in our opinion, perhaps the
single most important development will be the exploitation of
virotherapy much earlier in the disease process, as a first
responder component of the front line therapeutic regimens.
In this scenario, the prospects for long-term durable responses
look to be the highest.
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